Eritoran

Dec. 22/PRNewswire/-- The investigational compound, eritoran tetrasodium ( "eritoran," also known as E5564) appeared to be well tolerated in patients with severe sepsis in a Phase II trial published in the January issue of Critical Care ❋ Unknown (2010)

The investigational compound, eritoran tetrasodium ( "eritoran," also known as E5564) appeared to be ... ❋ Unknown (2010)

"We had focused on the drug eritoran as a major share price catalyst, on par with the life-cycle management strategy for Alzheimer's dementia treatment Aricept," Credit Suisse analyst F. ❋ Unknown (2011)

The company said the decision was based on test results, which showed eritoran didn't meet the expected outcome of lowering mortality rate in patients suffering from severe sepsis. ❋ Unknown (2011)

March 25/PRNewswire/-- Eisai Inc. announced today that the Phase III ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial of the investigational compound eritoran (E5564) will continue enrolling to the preset goal of 2,000 patients. ❋ Unknown (2010)

For more information regarding eritoran or ongoing clinical trials, please contact Eisai Medical Services at 1-888-422-4743. ❋ Unknown (2010)

Discovered and developed by Eisai, eritoran is believed to block activation of toll-like receptor 4 (TLR4). ❋ Unknown (2010)

Eisai's research and development efforts regarding eritoran and severe sepsis illustrate the company's human health care mission, which is to address unmet medical needs and increase benefits to patients and their families. ❋ Unknown (2010)

E5564 (eritoran) would continue to enroll patients to an agreed 2,000 patients. ❋ EP Vantage (2010)

While sales are currently forecast to hit $330m by 2014, given the nature of sepsis the company was predicting that the drug could eventually hit blockbuster status. eritoran will be a blow to those trying to find an effective treatment for sepsis. ❋ EP Vantage (2010)

+0.32% stock tumbled 5% after the company said Tuesday that it won't file marketing applications for the drug - currently in late-stage development with a generic name of eritoran - in the key markets of U.S., European Union, and Japan by the end of March, as it had originally planned. ❋ Unknown (2011)